2016 Fiscal Year Final Research Report
Development of NET theranosptic agents based on novel 64Cu-labeled somatostatin derivatives
| Project/Area Number |
15K19824
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Suzuka University of Medical Science |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Keywords | 神経内分泌腫瘍 / ソマトスタチン誘導体 / 64Cuキレーター / ATSM誘導体 / 診断／治療薬開発 |
|---|
| Outline of Final Research Achievements |
Radiolabeled somatostatin (SST) analogues are useful for diagnosis and therapy of neuroendcrine tumor (NET). The aim of this study is to develop a novel theranostic agent which enables to perform both diagnosis and therapy of NET, we designed and synthesized novel Cu-64-labeled SST analogues. Administration of them in the model mice implanted AR42J cells before acquiring time-dependent PET images contributed to obtain clear tumor images. In addition, higher accumulation of Cu-64 over a prolonged period to AR42J tumor were observed in mice administrated a novel radiolabeled SST than in mice administrated a reference SST analogue. These results suggest the usability of Cu-64-labeled SST analogue as a novel agent for NET diagnosis.
|
| Free Research Field |
創薬錯体化学
|
